OncoImmunity Receives €2.2 Million to Roll out Its Machine-Learning Platform to Enable the Development of Personalized Cancer Immunotherapies
The bioinformatics company OncoImmunity has been awarded the prestigious EU SME Instrument funding. The company’s flagship product, the ImmuneProfiler™, is a unique machine learning solution that has made inroads into solving the neoantigen prediction challenge. OncoImmunity enables their partners to solve the “needle in the haystack” challenge of identifying the right cocktail of neoantigens for each individual patient, and design a vaccine or cell therapy uniquely tailored to their specific tumor.
The machine learning company is based in both Oslo Norway and Cambridge Massachusetts in the USA, and this funding will advance further its capability to tailor the ImmuneProfiler™ for specific vaccine platforms, facilitating the design of safer and more efficacious personalized cancer vaccines.
- This project matches our ambition to position OncoImmunity as the leading supplier of neoantigen identification software in the personalized cancer vaccine market, says Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity.
- The ImmuneProfiler™ is already a powerful antigen presentation prediction tool, with demonstrated utility in predicting antigens that are presented and visible to a patient’s T cells. With these funds OncoImmunity will further advance its generic platform to learn the precise constellation of potential neoantigens that are immunogenic in different vaccine delivery systems, says Dr. Trevor Clancy, Chief Scientific Officer and Co-founder of OncoImmunity.
OncoImmunity is a machine-learning company offering a proprietary technology to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy, and identifies optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.
Trevor Clancy Ph.D.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
ABB19.1.2019 10:02 | Pressemeddelelse
Warm welcome for ABB Formula E in Davos
PHILIP-MORRIS-INTERNATIO18.1.2019 18:02 | Pressemeddelelse
PMI’s Mission Winnow Goes Full Throttle with Ducati Corse for 2019 MotoGP™
NY-IFF18.1.2019 13:52 | Pressemeddelelse
IFF’s Frutarom Division Completes Acquisition of 60% of Thailand-based Mighty
LARSEN-&-TOUBRO-INFOTECH18.1.2019 13:04 | Pressemeddelelse
LTI Q3 FY19: Constant currency revenue growth up 6.1% QoQ and 20.6% YoY; Net Profit jumps 32.8% YoY
TX-SCHLUMBERGER-LIMITED18.1.2019 13:02 | Pressemeddelelse
Schlumberger Announces Full-Year and Fourth-Quarter 2018 Results
OR-FLIR-SYSTEMS18.1.2019 12:02 | Pressemeddelelse
FLIR Systems Awarded $89 Million Contract from French Armed Forces to Deliver Black Hornet Personal Reconnaissance System
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum